Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

The most common cause of acquired thyroid dysfunction is autoimmune thyroid disease,
which is an organ-specific autoimmune disease with two presentation phenotypes …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of systemic
autoimmune diseases that affect the skeletal muscles and can also involve the skin, joints …

The pathogenesis of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and
other forms of interstitial lung disease, involves a complex interplay of various factors …

Immune checkpoint inhibitor therapies act through blockade of inhibitory molecules involved
in the regulation of T cells, thus releasing tumor specific T cells to destroy their tumor targets …

Background Immune-related adverse events (irAEs) are a common phenomenon in cancer
patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, their use
is frequently associated with immune‐related adverse events (irAEs) potentially affecting …

Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of various cancer
types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting …

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative
checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role …